PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...

A 36-week treatment regimen of pegcetacoplan reduces geographic atrophy growth rate while demonstrating a favorable safety profile.

In advanced stages, dry AMD progresses into geographic atrophy (GA), characterized by atrophy of the retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris, responsible for a ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...

Outer retinal tubulation may slow lesion growth in eyes with geographic atrophy secondary to age-related macular degeneration.

Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight-robbing condition that accompanies age-related macular degeneration (AMD ...

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).